Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions
Status:
Completed
Trial end date:
2003-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the relative bioavailability of Moexipril
HCl/hydrochlorothiazide 15/25 mg tablets (manufactured and distributed by TEVA
Pharmaceuticals USA) with that of UNIRETIC® 15/25 mg tablets (Schwartz Pharma) in healthy,
adult non-smoking subjects under fasting conditions.